Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 28, 2022; 28(40): 5818-5826
Published online Oct 28, 2022. doi: 10.3748/wjg.v28.i40.5818
Published online Oct 28, 2022. doi: 10.3748/wjg.v28.i40.5818
Management of liver diseases: Current perspectives
Gautam Ray, Gastroenterology Unit, Department of Medicine, B.R.Singh (Railway) Hospital, Kolkata 700014, West Bengal, India
Author contributions: Ray G conceptualized the topic, collected data, drafted, edited and approved the final manuscript.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gautam Ray, DNB, MD, Academic Research, Chief Doctor, Doctor, Teacher, Gastroenterology Unit, Department of Medicine, B.R.Singh (Railway) Hospital, Parikshit Roy Lane, Near Sealdah Bus Stop, Beliaghata, Kolkata 700014, West Bengal, India. gautam1910@yahoo.com
Received: July 10, 2022
Peer-review started: July 10, 2022
First decision: July 31, 2022
Revised: August 4, 2022
Accepted: September 21, 2022
Article in press: September 21, 2022
Published online: October 28, 2022
Peer-review started: July 10, 2022
First decision: July 31, 2022
Revised: August 4, 2022
Accepted: September 21, 2022
Article in press: September 21, 2022
Published online: October 28, 2022
Core Tip
Core Tip: The incidence and prevalence of liver disease is rising all over the world. Hepatitis B is difficult to eradicate and the benefit of directly acting antiviral therapy for hepatitis C is partially offset by increasing IV drug abuse. Non-alcoholic fatty liver disease pandemic is on and alcohol related liver disease is rising alarmingly, both having no drug cure. Due to better management of complications, patients of chronic liver disease are living longer spiking the number of hepatocellular carcinoma (HCC) and patients needing liver transplantation (LT). Better diagnostics and therapeutics are available for fibrosis, portal hypertension, HCC and post LT management which are discussed.